Valsartan and Hydrochlorothiazide · VALSARTAN 160 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 · Tablet · Oral · Macleods Pharmaceuticals Limited
NDC 33342-0076-10 · 90 TABLET in 1 BOTTLE · ANDA · View full market →
Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The price is down 27% over the past year, to $0.1245 per unit. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Some pressure is visible, but not much — here’s everything the score found to count.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
OAI inspection at a producing facility (24 months) · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | VALSARTAN 160 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Macleods Pharmaceuticals Limited | VALSARTAN 160 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Northwind Health Company, LLC | VALSARTAN 160 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| A-S Medication Solutions | VALSARTAN 25 mg/1; HYDROCHLOROTHIAZIDE 160 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Macleods Pharmaceuticals Limited | VALSARTAN 25 mg/1; HYDROCHLOROTHIAZIDE 160 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Northwind Health Company, LLC | VALSARTAN 25 mg/1; HYDROCHLOROTHIAZIDE 160 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| A-S Medication Solutions | HYDROCHLOROTHIAZIDE 25 mg/1; VALSARTAN 160 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Macleods Pharmaceuticals Limited | HYDROCHLOROTHIAZIDE 25 mg/1; VALSARTAN 160 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Northwind Health Company, LLC | HYDROCHLOROTHIAZIDE 25 mg/1; VALSARTAN 160 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Valsartan and Hydrochlorothiazide — NDC 33342-0076-10," retrieved September 3, 2026, https://drugdashboards.com/drug/33342007610.
Free to cite with attribution — see how the data is put together.